Evolved Antibody-drug Conjugates Raw Materials

Overview of ADCs

Antibody-Drug Conjugates (ADCs), known as "biological missiles", combine tumor-targeting specificity of monoclonal antibodies with potent cytotoxic payloads. ADC drug development encounters severe technical challenges across target identification, linker engineering, conjugation chemistry and preclinical pharmacodynamic characterization.

ANTBIO delivers a full-spectrum ADC research toolkit including raw materials, conjugation reagents and comprehensive detection kits to accelerate your ADC pipeline development.

Figure 1. Schematic diagram of ADC structure

ADC Core Raw Materials

1. Cytotoxic Payloads

• High purity with potent tumor growth suppression activity
• Favorable in vivo pharmacokinetic profiles
• Membrane permeability to induce bystander effect

2. ADC Linkers & Pre-Assembled Linker-Payload Conjugates

• High-purity ADC linkers available
• Two major categories: cleavable linkers and non-cleavable linkers

Table 1: Payloads + Linkers + Linker-Payload Conjugates

Drug Conjugation

1. Sortase A-Mediated Enzymatic Conjugation (SMAC)

Sortase A recognizes the conserved LPXTG peptide motif and cleaves the bond between threonine and glycine residues. SMAC enables site-specific toxin attachment at predefined antibody loci to generate highly homogeneous, stable ADCs with uniform DAR values.

Table 2: Sortase A

• High Catalytic Efficiency: Site-specific protein ligation with intact native structure and bioactivity
• Sequence-Specific Recognition: LPXTG-dependent coupling compatible with glycine-modified acceptors and broad substrates
• Mild Reaction Conditions: Physiological buffer conditions eliminate protein degradation risks
• Tunable Reaction Kinetics: Adjust calcium concentration, substrate dosage and incubation time to optimize yield and conjugation efficiency

2. Glycan-Based Conjugation Toolkit

Table 3: Glycosidase Reagents for Glycan Editing

• Superior Homogeneity: Site-specific glycan modification achieves uniform drug loading for homogeneous ADC batches
• Enhanced Stability: Preserves full antibody bioactivity; engineered glycans improve ADC structural stability and biocompatibility
• Improved Therapeutic Window: Reduced off-target cytotoxicity and expanded safety margin for in vivo applications

3. Complete Site-Directed Conjugation Kits

Step 1: Antibody Azide Modification

EndoS glycosidase trims antibody conserved N-glycans to expose terminal GlcNAc. Mutant β-galactosyltransferase (b.GalTY289L) transfers azide-functionalized GalNAz onto exposed GlcNAc via UDP-GalNAz substrate.

Figure 2. Antibody Azide Modification

Step 2: Cytotoxin Click Conjugation

Copper-free SPAAC click chemistry conjugates cytotoxins, biotin or fluorescent probes to azide-modified antibodies.

Figure 3. Cytotoxin Click Conjugation

Table 4: Site-Directed Conjugation Kits

• Simple Operation: No prior antibody genetic engineering required
• Rapid Site-Specific Labeling: Fast covalent coupling on native monoclonal antibodies
• Uniform Conjugates: Final ADC products exhibit high homogeneity and long-term stability